Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Raw Materials (2022 - 2024)

Atara Biotherapeutics filings provide 3 years of Raw Materials readings, the most recent being $964000.0 for Q4 2024.

  • On a quarterly basis, Raw Materials fell 58.72% to $964000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $964000.0, a 58.72% decrease, with the full-year FY2024 number at $964000.0, down 58.72% from a year prior.
  • Raw Materials hit $964000.0 in Q4 2024 for Atara Biotherapeutics, down from $1.7 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $4.4 million in Q1 2024 to a low of $964000.0 in Q4 2024.
  • Median Raw Materials over the past 3 years was $2.3 million (2023), compared with a mean of $2.3 million.
  • The widest YoY moves for Raw Materials: up 229.38% in 2024, down 58.72% in 2024.
  • Atara Biotherapeutics' Raw Materials stood at $1.2 million in 2022, then skyrocketed by 92.34% to $2.3 million in 2023, then crashed by 58.72% to $964000.0 in 2024.
  • The last three reported values for Raw Materials were $964000.0 (Q4 2024), $1.7 million (Q3 2024), and $3.6 million (Q2 2024) per Business Quant data.